These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24825198)

  • 1. The relationship between pediatric combination vaccines and market effects.
    Behzad B; Jacobson SH; Jokela JA; Sewell EC
    Am J Public Health; 2014 Jun; 104(6):998-1004. PubMed ID: 24825198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing strategies for combination pediatric vaccines and their impact on revenue: Pediarix or Pentacel?
    Robbins MJ; Jacobson SH; Sewell EC
    Health Care Manag Sci; 2010 Mar; 13(1):54-64. PubMed ID: 20402282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact of Infanrix hexa (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 1: Evolution of hepatitis B vaccine coverage rates in infants aged less than 27 months, in the general population - the PopCorn study.
    Gaudelus J; Vié le Sage F; Dufour V; Lert F; Texier N; Pouriel M; Tehard B; Bréart G
    Rev Epidemiol Sante Publique; 2016 Feb; 64(1):23-32. PubMed ID: 26748972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact of Infanrix hexa™ (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 2: Evolution of the acceptability of infants' vaccination against hepatitis B in general and pediatric practices - the PRALINE study.
    Vié le Sage F; Gaudelus J; Lert F; Dufour V; Texier N; Pouriel M; Schück S; Tehard B; Bréart G
    Rev Epidemiol Sante Publique; 2016 Jun; 64(3):185-94. PubMed ID: 27238163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.
    Monge S; Hahné SJ; de Melker HE; Sanders EA; van der Ende A; Knol MJ
    Lancet Infect Dis; 2018 Jul; 18(7):749-757. PubMed ID: 29752131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection.
    Weniger BG; Chen RT; Jacobson SH; Sewell EC; Deuson R; Livengood JR; Orenstein WA
    Vaccine; 1998 Nov; 16(19):1885-97. PubMed ID: 9795397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine.
    Olivera I; Grau C; Dibarboure H; Torres JP; Mieres G; Lazarov L; Alvarez FP; Yescas JGL
    BMC Health Serv Res; 2020 Apr; 20(1):295. PubMed ID: 32272920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran.
    Teimouri F; Kebriaeezadeh A; Zahraei SM; Gheiratian M; Nikfar S
    Daru; 2017 Jan; 25(1):1. PubMed ID: 28088246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a new combined vaccine in pediatric practices.
    Freed GL; Cowan AE; Clark SJ; Santoli J; Bradley J
    Pediatrics; 2006 Aug; 118(2):e251-7. PubMed ID: 16831895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyzing the economic value of the hepatitis B--Haemophilus influenzae type B combination vaccine by reverse engineering a formulary selection algorithm.
    Jacobson SH; Karnani T; Sewell EC
    Vaccine; 2003 May; 21(17-18):2169-77. PubMed ID: 12706708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Feb; 33(ACS-1):1-14. PubMed ID: 17294559
    [No Abstract]   [Full Text] [Related]  

  • 12. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejoinder to comments on ''Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China''.
    Amimo F
    Hum Vaccin Immunother; 2024 Dec; 20(1):2375668. PubMed ID: 39024500
    [No Abstract]   [Full Text] [Related]  

  • 14. "Reverse engineering" a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines.
    Sewell EC; Jacobson SH; Weniger BG
    Pediatr Infect Dis J; 2001 Nov; 20(11 Suppl):S45-56. PubMed ID: 11704724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea.
    Kim YK; Vidor E; Kim HM; Shin SM; Lee KY; Cha SH; Ma SH; Kim DH; Lee J; Park SE; Lee H; Kim JD; Kim KH; Kim KH; Kim JH;
    Vaccine; 2017 Jul; 35(32):4022-4028. PubMed ID: 28629923
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of vaccine procurement methods on public health in selected European countries.
    Wilsdon T; Lawlor R; Li L; Rafila A; García Rojas A
    Expert Rev Vaccines; 2020 Feb; 19(2):123-132. PubMed ID: 31990601
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.
    Itell HL; McGuire EP; Muresan P; Cunningham CK; McFarland EJ; Borkowsky W; Permar SR; Fouda GG
    Vaccine; 2018 Sep; 36(37):5600-5608. PubMed ID: 30087048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
    Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
    Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine.
    Arístegui J; Usonis V; Coovadia H; Riedemann S; Win KM; Gatchalian S; Bock HL
    Int J Infect Dis; 2003 Jun; 7(2):143-51. PubMed ID: 12839717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
    Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
    Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.